DeepWell DTx makes digital therapeutic technology that can be integrated with media to create new approaches for treating mental and physical health conditions. Launched in 2022, DeepWell holds several patents, with 20 more pending, for transforming media into medicine.
DeepWell DTx is part of NeuFluent, a venture studio developing neuroscience innovation — novel components, systems, and processes for highly reliable interconnectivity that streams data to digitally native processing and communication platforms. NeuFluent technology promotes accelerated adoption of new behaviors, self-discovery, and learning. NeuFluent holds multiple patents in dynamically controlled shunts, distributed sensing and control, central nervous system monitoring and interventions, spinal fluid polarization, therapeutics augmentation, AI based managed care, brain computer interfaces, and more.